Insmed Incorporated
INSMNASDAQHealthcare● Active
$94.22
$-10.70(-10.20%)
Market Cap$20.4B
P/E Ratio—
52W High$212.75
52W Low$70.57
Insmed Incorporated (INSM) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
INSM · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
-$0.76
Est. -$0.96 · +21.1%
Revenue
$0.31B
Est. $0.30B · +1.7%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue✓ 1-Quarter EPS Beat Streak
INSM reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.84B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.84B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | -$0.76 | — | — | — | $0.39B | — |
| ▲ Q2 FY2026 | May 7, 2026 | -$0.96 | -$0.76 | +21.1% | $0.31B | $0.30B | +1.7% |
| ▼ Q1 FY2026 | Feb 19, 2026 | -$1.07 | -$1.54 | -43.9% | $0.26B | $0.23B | +14.1% |
| ▼ Q4 FY2025 | Oct 30, 2025 | -$1.33 | -$1.75 | -31.6% | $0.14B | $0.12B | +23.3% |
| ▼ Q3 FY2025 | Aug 7, 2025 | -$1.30 | -$1.70 | -30.8% | $0.11B | $0.10B | +3.2% |
| ▼ Q2 FY2025 | May 8, 2025 | -$1.34 | -$1.42 | -6.0% | $0.09B | $0.09B | +1.5% |
| ▼ Q1 FY2025 | Feb 20, 2025 | -$1.17 | -$1.32 | -12.8% | $0.10B | $0.10B | +2.3% |
| ▼ Q4 FY2024 | Oct 31, 2024 | -$1.20 | -$1.27 | -5.8% | $0.09B | $0.09B | +0.1% |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
-$0.76
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026Beat
EPS Actual
-$0.76
EPS Est.
-$0.96
EPS Surpr.
+21.1%
Revenue
$0.31B
Q1 FY2026
Feb 19, 2026Miss
EPS Actual
-$1.54
EPS Est.
-$1.07
EPS Surpr.
-43.9%
Revenue
$0.26B
Q4 FY2025
Oct 30, 2025Miss
EPS Actual
-$1.75
EPS Est.
-$1.33
EPS Surpr.
-31.6%
Revenue
$0.14B
Q3 FY2025
Aug 7, 2025Miss
EPS Actual
-$1.70
EPS Est.
-$1.30
EPS Surpr.
-30.8%
Revenue
$0.11B
Q2 FY2025
May 8, 2025Miss
EPS Actual
-$1.42
EPS Est.
-$1.34
EPS Surpr.
-6.0%
Revenue
$0.09B
Q1 FY2025
Feb 20, 2025Miss
EPS Actual
-$1.32
EPS Est.
-$1.17
EPS Surpr.
-12.8%
Revenue
$0.10B
Q4 FY2024
Oct 31, 2024Miss
EPS Actual
-$1.27
EPS Est.
-$1.20
EPS Surpr.
-5.8%
Revenue
$0.09B
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.85 | $0.92 | $0.99 | 5 |
| Q3 FY2028 | $0.73 | $0.79 | $0.85 | 5 |
| Q2 FY2028 | $0.60 | $0.65 | $0.70 | 5 |
| Q1 FY2028 | $0.44 | $0.48 | $0.52 | 5 |
| Q4 FY2027 | $0.50 | $0.54 | $0.58 | 4 |
| Q3 FY2027 | $0.31 | $0.34 | $0.36 | 4 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.9B | $0.9B | $1.0B | 8 |
| Q3 FY2028 | $0.8B | $0.9B | $0.9B | 6 |
| Q2 FY2028 | $0.8B | $0.8B | $0.9B | 5 |
| Q1 FY2028 | $0.7B | $0.8B | $0.8B | 5 |
| Q4 FY2027 | $0.7B | $0.7B | $0.8B | 6 |
| Q3 FY2027 | $0.6B | $0.7B | $0.7B | 6 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 7, 2026 | +21.1% | $137.09 | $105.00 | -23.41% |
| ▼ Q1 FY2026 | Feb 19, 2026 | -43.9% | $151.11 | $161.00 | +6.54% |
| ▼ Q4 FY2025 | Oct 30, 2025 | -31.6% | $166.95 | $194.22 | +16.33% |
| ▼ Q3 FY2025 | Aug 7, 2025 | -30.8% | $111.26 | $109.30 | -1.76% |
| ▼ Q2 FY2025 | May 8, 2025 | -6.0% | $68.28 | $65.63 | -3.88% |
| ▼ Q1 FY2025 | Feb 20, 2025 | -12.8% | $83.83 | $83.61 | -0.26% |
| ▼ Q4 FY2024 | Oct 31, 2024 | -5.8% | $70.30 | $67.28 | -4.30% |
| ▼ Q3 FY2024 | Aug 8, 2024 | -56.5% | $70.99 | $71.81 | +1.16% |
Q2 FY2026-23.41%
Report Date
May 7, 2026
EPS Beat/Miss
+21.1%
Price Before
$137.09
Price After
$105.00
Q1 FY2026+6.54%
Report Date
Feb 19, 2026
EPS Beat/Miss
-43.9%
Price Before
$151.11
Price After
$161.00
Q4 FY2025+16.33%
Report Date
Oct 30, 2025
EPS Beat/Miss
-31.6%
Price Before
$166.95
Price After
$194.22
Q3 FY2025-1.76%
Report Date
Aug 7, 2025
EPS Beat/Miss
-30.8%
Price Before
$111.26
Price After
$109.30
Q2 FY2025-3.88%
Report Date
May 8, 2025
EPS Beat/Miss
-6.0%
Price Before
$68.28
Price After
$65.63
Q1 FY2025-0.26%
Report Date
Feb 20, 2025
EPS Beat/Miss
-12.8%
Price Before
$83.83
Price After
$83.61
Q4 FY2024-4.30%
Report Date
Oct 31, 2024
EPS Beat/Miss
-5.8%
Price Before
$70.30
Price After
$67.28
Q3 FY2024+1.16%
Report Date
Aug 8, 2024
EPS Beat/Miss
-56.5%
Price Before
$70.99
Price After
$71.81
Avg Beat Reaction-23.41%
Avg Miss Reaction+1.98%
Beat Rate1 / 8 quarters
Largest Move-23.41% (Q2 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: INSM ends December
Insmed Incorporated (INSM) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $-0.76 — beating the analyst consensus of $-0.96 by +21.1%. The next INSM earnings date is expected around September 1, 2026.
Each quarter, investors track INSM earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. INSM revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
INSM's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
INSM earnings · 5 questionsInsmed Incorporated's next earnings report is expected around September 1, 2026. INSM typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; INSM historically reports after market close (AMC).
INSM earnings datewhen is INSM earningsINSM next earnings datewhen does INSM report earningsINSM earnings calendar
▸ Source: FMP · Insmed Incorporated SEC filings · US GAAP · Insmed Incorporated SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026